RxDoctor Payments Data

Megan Hoffield

Medical · Ardmore, OKNPI 1285713065

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.6% of the total across 207 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Novartis at 26.1% of the total.

$3,935in general payments, 2019–2025

Across 207 payments — averaging $19.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • UCB, Inc.$626
  • Lilly USA, LLC$572
  • Johnson & Johnson$368
  • Regeneron Healthcare Solutions, Inc.$264
  • E.r. Squibb & Sons, L.L.C.$256
  • plus $820 from 11 others

What the payments were for

  • Food & beverage$3,84298%
  • Education$932%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,935 in reported general payments places this provider in the 85th percentile of 370 medical providers in Oklahoma.

See all medical providers in Oklahoma

Medicare billing

Part B allowed, 2024
$368,997
Medicare patients
1,582
Services billed
7,337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$241,009
Dupixent PenDupilumab57$228,837
Cosentyx Sensoready (2 Pens)Secukinumab26$195,138
Taltz Autoinjector (2 Pack)Ixekizumab14$192,490
Humira(Cf) PenAdalimumab13$164,689
Taltz AutoinjectorIxekizumab11$158,917
OtezlaApremilast24$119,640
AdbryTralokinumab-Ldrm19$74,219
Clobetasol Propionate217$12,239
Tacrolimus39$6,154
Ketoconazole189$2,813
Triamcinolone Acetonide164$2,427
Metronidazole26$1,314
ValacyclovirValacyclovir Hcl46$1,287
Fluocinolone AcetonideFluocinolone/Shower Cap26$1,275

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$54$119,64024 claims
LEO Pharma Inc.Adbry$62$74,21919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 370 medical providers in Oklahoma.

Other medical in Ardmore

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →